ADMA Biologics, Inc. (ADMA)
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
- Symbol
- ADMA
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $2.19B
- 52 week range
- 7.21 - 20.46
Valuation
- Share price
- $9.70 (close of 2026-09-23)
- P/E (TTM)
- 13.29x
- Price to book
- 5.35x
- Price to free cash flow
- 18.77x
- Enterprise value
- $2.25B
- Book value per share
- $1.81
Price performance
| Period | Change |
|---|
| 1 day | +2.00% |
| 5 days | +12.66% |
| 1 month | -1.42% |
| 3 months | +11.62% |
| 6 months | -28.62% |
| Year to date | -46.82% |
| 1 year | -39.30% |
| 3 years | +176.35% |
| 5 years | +657.81% |
| 10 years | +31.98% |
| All time | +13.45% |
Profitability and growth
- Return on equity
- 30.78%
- Return on invested capital
- 33.16%
- Return on assets
- 23.54%
- Return on capital employed
- 34.51%
- Gross margin
- 57.39%
- Net margin
- 28.80%
- EBITDA margin
- 39.11%
- Revenue growth
- 19.63%
- Net income growth
- -25.67%
- Free cash flow growth
- -74.81%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 5.33%
- Current ratio
- 6.97x
- Net debt to EBITDA
- 0.29x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $510.17M
- Cost of revenue
- $217.41M
- Gross profit
- $292.76M
- EBITDA
- $199.54M
- Net income
- $146.93M
- Earnings per share
- $0.62
- Research and development
- $4.76M
- Shares outstanding
- 238.30M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $510.17M | $292.76M | $146.93M | $0.62 |
| 2024-12-31 | $426.45M | $219.55M | $197.67M | $0.85 |
| 2023-12-31 | $258.21M | $88.94M | $-28.24M | $-0.13 |
| 2022-12-31 | $154.08M | $35.27M | $-65.90M | $-0.33 |
| 2021-12-31 | $80.94M | $1.17M | $-71.65M | $-0.51 |
| 2020-12-31 | $42.22M | $-19.07M | $-75.75M | $-0.88 |
| 2019-12-31 | $29.35M | $-10.16M | $-48.28M | $-0.89 |
| 2018-12-31 | $16.99M | $-25.21M | $-65.74M | $-1.45 |
| 2017-12-31 | $22.76M | $-6.40M | $-43.76M | $-1.91 |
| 2016-12-31 | $10.66M | $4.30M | $-19.52M | $-1.61 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 57.39% | 28.80% | 30.78% | 33.16% |
| 2024-12-31 | 51.48% | 46.35% | 56.64% | 42.37% |
| 2023-12-31 | 34.44% | -10.94% | -20.89% | 9.60% |
| 2022-12-31 | 22.89% | -42.77% | -43.37% | -17.90% |
| 2021-12-31 | 1.45% | -88.52% | -50.75% | -59.48% |
| 2020-12-31 | -45.17% | -179.41% | -85.84% | -175.31% |
| 2019-12-31 | -34.60% | -164.50% | -184.32% | - |
| 2018-12-31 | -148.42% | -387.06% | -332.53% | - |
| 2017-12-31 | -28.14% | -192.26% | -108.49% | - |
| 2016-12-31 | 40.34% | -183.05% | 437.83% | - |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $87.63M | $69.33M |
| 2024-12-31 | $103.15M | $72.34M |
| 2023-12-31 | $51.35M | - |
| 2022-12-31 | $86.52M | - |
| 2021-12-31 | $51.09M | - |
| 2020-12-31 | $55.92M | - |
| 2019-12-31 | $26.75M | - |
| 2018-12-31 | $26.75M | $2.76M |
| 2017-12-31 | $43.11M | $2.76M |
| 2016-12-31 | $15.31M | $1.79M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $27.82M | $20.03M |
| 2024-12-31 | $110.45M | $13.62M |
| 2023-12-31 | $4.03M | $6.19M |
| 2022-12-31 | $-73.42M | $5.21M |
| 2021-12-31 | $-125.88M | $3.49M |
| 2020-12-31 | $-114.73M | $2.86M |
| 2019-12-31 | $-80.01M | $2.65M |
| 2018-12-31 | $-64.77M | $2.22M |
| 2017-12-31 | $-39.95M | $1.56M |
| 2016-12-31 | $-18.34M | $1.25M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-04
- Consensus EPS estimate
- $0.19
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-08-05 | Jun/2026 | $0.16 |
| 2026-05-06 | - | - |
| 2026-02-25 | - | - |
| 2025-11-05 | - | - |
| 2025-08-06 | - | - |
| 2025-05-07 | - | - |
| 2025-03-03 | - | - |
| 2025-02-26 | - | - |
Filings and sources
- Company website
- admabiologics.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · IQVIA Holdings Inc. (IQV)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades